Initial double combination therapy with OPSUMIT and tadalafil led to significant improvements from baseline to Week 16 in cardiopulmonary haemodynamics (except reduction in mRAP is non-significant ), functional parameters, NT-proBNP and risk profile in newly diagnosed, treatment-naïve patients with PAH.1
References:
[1] Sibton O, Cottin V, Canuet M, et al. initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020 Sep 3;56 (3):2000673.
[2] OPSUMIT SmPC, April 2020. Available at: https://www.ema.europa.eu/en/d... en.pdf (last accessed October 2020).
[3] OPSUMIT Ministry of health approved leaflet 15/10/2018
CP-263136